Combined SYBR Green real-time polymerase chain reaction and microarray method for the simultaneous determination of human papillomavirus loads and genotypes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThe aim of this study was to describe the principle of the Cheil HPV DNA Chip assay and evaluate its accuracy. In order to quantify the human papillomavirus (HPV) load and identify HPV genotypes simultaneously, this assay combined the two methods: SYBR Green quantitative real-time polymerase chain reaction (PCR) and DNA microarray. MethodsWe designed novel consensus primer sets that target the conserved region of the HPV L1 gene for quantifying and detecting a broad range of HPV types by quantitative real-time PCR. Subsequently, using the PCR products, DNA microarray was performed with 36 HPV type-specific probes. To validate this method, direct sequencing and correlation analysis among HPV genotype, viral load, and cytological abnormality was performed by Cohen’s kappa values, two-sided McNemar chi-square test, Kruskal-Wallis test, and odds ratios. ResultsThe kappa value of the Cheil HPV DNA Chip was 0.963 (95% confidence interval, 0.919 to 0.98), which was significantly higher than the value of 0.527 (95% confidence interval, 0.447 to 0.59) obtained using a conventional HPV DNA Chip. HPV16 (χ2=62.28, P<0.01), HPV33 (χ2=7.18, P<0.01), and HPV58 (χ2=9.52, P<0.01), which are classified as high-risk HPVs, were detected at significant levels in samples with high-grade lesions. And viral loads tended to be higher in groups with high odds ratios. ConclusionThe Cheil HPV DNA Chip is an effective diagnostic assay for simultaneously detecting HPV genotypes and loads in cervical samples.
Abstract
ObjectiveThe aim of this study was to describe the principle of the Cheil HPV DNA Chip assay and evaluate its accuracy. In order to quantify the human papillomavirus (HPV) load and identify HPV genotypes simultaneously, this assay combined the two methods: SYBR Green quantitative real-time polymerase chain reaction (PCR) and DNA microarray. MethodsWe designed novel consensus primer sets that target the conserved region of the HPV L1 gene for quantifying and detecting a broad range of HPV types by quantitative real-time PCR. Subsequently, using the PCR products, DNA microarray was performed with 36 HPV type-specific probes. To validate this method, direct sequencing and correlation analysis among HPV genotype, viral load, and cytological abnormality was performed by Cohen’s kappa values, two-sided McNemar chi-square test, Kruskal-Wallis test, and odds ratios. ResultsThe kappa value of the Cheil HPV DNA Chip was 0.963 (95% confidence interval, 0.919 to 0.98), which was significantly higher than the value of 0.527 (95% confidence interval, 0.447 to 0.59) obtained using a conventional HPV DNA Chip. HPV16 (χ2=62.28, P<0.01), HPV33 (χ2=7.18, P<0.01), and HPV58 (χ2=9.52, P<0.01), which are classified as high-risk HPVs, were detected at significant levels in samples with high-grade lesions. And viral loads tended to be higher in groups with high odds ratios. ConclusionThe Cheil HPV DNA Chip is an effective diagnostic assay for simultaneously detecting HPV genotypes and loads in cervical samples.
참고문헌 (26)
- Dalstein V, "Persistence and load of highrisk HPV are predictors for development of high-grade cervical lesions : a longitudinal French cohort study", Int J Cancer, 106, pp.396~403 (2003)
- Schlecht NF, "Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia", JAMA, 286, pp.3106~3114 (2001)
- Lorincz AT, "Human papillomavirus infection of the cervix : relative risk associations of 15 common anogenital types", Obstet Gynecol, 79, pp.328~337 (1992)
- Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J Pathol, 189, pp.12~19 (1999)
- Heard I, "Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load", Obstet Gynecol, 96, pp.403~409 (2000)
- Lai HC, "Differential viral loads of human papillomavirus 16and 58 infections in the spectrum of cervical carcinogenesis", Int J Gynecol Cancer, 16, pp.730~735 (2006)
- Roberts I, "Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR", BMC Biotechnol, 8, pp.57~ (2008)
- Ramanakumar AV, "Human papillomavirus (HPV)types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women", BMC Infect Dis, 10, pp.326~ (2010)
- Arias-Pulido H, "Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer", J Clin Microbiol, 44, pp.1755~1762 (2006)
- Vaccarella S, "Concurrent infection with multiple human papillomavirus types : pooled analysis of the IARC HPV Prevalence Surveys", Cancer Epidemiol Biomarkers Prev, 19, pp.503~510 (2010)
- Schmitt M, "Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities", J Clin Microbiol, 51, pp.1458~1464 (2013)
- e-Castro Arce J, "Retinoic acid receptor beta silences human papillomavirus-18 oncogene expression by induction of de novo methylation and heterochromatinization of the viral control region", J Biol Chem, 282, pp.28520~28529 (2007)
- Carbone M, "Modern criteria to establish human cancer etiology", Cancer Res, 64, pp.5518~5524 (2004)
- Santos AL, "Human papillomavirus viral load in predicting high-grade CIN in women with cervical smears showing only atypical squamous cells or lowgrade squamous intraepithelial lesion", Sao Paulo Med J, 121, pp.238~243 (2003)
- Broccolo F, "Prevalence and viral load of oncogenic human papillomavirus types associated with cervical carcinoma in a population of North Italy", J Med Virol, 81, pp.278~287 (2009)
- Murall CL, "Could the human papillomavirus vaccines drive virulence evolution?", Proc Biol Sci, 282, pp.20141069~ (2015)
- Elfstrom KM, "Organization and quality of HPV vaccination programs in Europe", Vaccine, 33, pp.1673~1681 (2015)
- Ramaiah Vinay Kumar, "Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV", Journal of Gynecologic Oncology, 24(4), pp.295~297 (2013), 대한부인종양학회
- Kim TJ, "Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients", Nat Commun, 5, pp.5317~ (2014)
- Fleiss JL, "Statistical methods for rates and proportions" (1981), John Wiley and Sons
- Cai YP, "Comparison of human papillomavirus detection and genotyping with four different prime sets by PCR-sequencing", Biomed Environ Sci, 26, pp.40~47 (2013)
- Husnjak K, "Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens", J Virol Methods, 88, pp.125~134 (2000)
- Bae, Jeong-Hoon, "Human Papillomavirus (HPV) Type Distribution in Korean Women: A Meta-Analysis", Journal of Microbiology and Biotechnology, 18(4), pp.788~794 (2008), 한국미생물·생명공학회
- Hariri S, "Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006", J Infect Dis, 204, pp.566~573 (2011)
- Hwang HS, "Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 korean women determined by DNA chip", Cancer Epidemiol Biomarkers Prev, 13, pp.2153~2156 (2004)
- An HJ, "Correlation of cervical carcinoma and precancerous lesions with human papillomavirus(HPV)genotypes detected with the HPV DNA chip microarray method", Cancer, 97, pp.1672~1680 (2003)